Clinical Trials for Patients with Liver Diseases
Gabapentin for the Treatment of Itch Due to Liver Disease
At present, we are conducting a NIH-funded double blind, placebo-controlled
study on the use of the drug gabapentin for the treatment of the itch due to
liver disease (IRB Protocol #9618). Study participants will be evaluated in
the outpatient facility of the Irving Center for Clinical Investigation at
the New York Presbyterian Hospital Columbia-Presbyterian Center in New York
City. Once eligibility status is confirmed, participants will be admitted
for baseline evaluation of itch before and after completion of the four week
treatment period. There are some travel funds available for participants
from outside the tri-state area.
All participants must be referred by their physician, who will
continue to render medical care. The physicians will receive a summary of
the participant's results at the end of the treatment phase.
Contact for Information:
Nora V. Bergasa, M. D.
Phone: 212-305-1021
Email: nb343@columbia.edu
![[help]](/images/buttons/help.gif)
